Rezdiffra (Resmetirom) Geriatric Safety: What Adults 65 and Older Need to Know

Resmetirom (brand name Rezdiffra) is an oral, liver-directed, selective thyroid hormone receptor beta (THR-β) agonist. The FDA approved it in March 2024 for adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis (stage F2-F3), given alongside diet and exercise. It is not FDA-approved for cirrhosis, and it is not the same drug class as GLP-1 agonists or other MASH candidates in development. Age 65 and older is not a labeled contraindication, but the trial base behind that reassurance is thinner than for a drug with decades of market history.

The direct answer

Resmetirom's FDA label does not restrict use by age and does not specify an age-based dose adjustment; dosing is weight-based (80 mg daily under 100 kg, 100 mg daily at or above 100 kg). Older adults were included in the pivotal trial population that supported approval, but the trial was sized to detect an overall treatment effect, not a geriatric-specific safety signal, so absence of a flagged problem in that subgroup is reassuring rather than definitive. For a patient 65 or older, the practical safety question is not "is this drug approved for my age" but "does my thyroid axis, liver reserve, kidney function, and medication list tolerate closer monitoring than the standard protocol calls for."

What is established, what is plausible, and what is not established

Established from the FDA label: the approved indication (MASH with F2-F3 fibrosis), the weight-based dosing, the recommendation for baseline and periodic liver enzyme monitoring, and specific dose caps for rosuvastatin (20 mg) and pitavastatin (2 mg) when co-administered because resmetirom raises exposure to statins cleared through OATP1B1/OATP1B3 transporters.

Plausible but not established by dedicated geriatric data: that thyroid-axis suppression from resmetirom carries the same low risk profile in adults over 65 as in younger trial participants, given that even mild TSH suppression is associated with cardiovascular and fracture risk in older populations generally. This is a reasonable inference from the drug's THR-β selectivity, not a geriatric-specific finding.

Not established: long-term (multi-year) safety in adults 65 and older, safety in decompensated cirrhosis (Child-Pugh B or C, which the pivotal trial excluded), and safety in advanced chronic kidney disease (eGFR below 30 mL/min/1.73 m², also excluded from the pivotal trial population).

Why age changes the risk calculus even without a label warning

Liver blood flow and hepatic clearance capacity decline with age, and resmetirom is cleared primarily through hepatic metabolism (CYP3A4, CYP2C8, and glucuronidation pathways per the FDA label). A patient with reduced hepatic reserve, whether from age-related decline or from the underlying liver disease resmetirom is meant to treat, may experience different drug exposure than a younger trial participant even without a formal dose-adjustment requirement. Renal function also declines gradually with age, and although resmetirom is not primarily renally eliminated, comorbid kidney impairment affects how well a patient tolerates GI side effects like diarrhea, which can cause dehydration and secondary kidney stress.

Polypharmacy compounds this. Older adults commonly take multiple prescription medications, and each additional CYP3A4/CYP2C8 substrate, OATP transporter substrate, or thyroid-axis-active drug increases the interaction surface. This is the core reason a geriatric safety discussion for resmetirom is not simply "is it approved for this age" but "what else is this patient taking."

What the pivotal trial showed, and its limits

The trial that supported FDA approval (commonly referred to as MAESTRO-NASH) enrolled adults 18 and older with biopsy-confirmed MASH and fibrosis stage F1B-F3, followed for 52 weeks against co-primary endpoints of MASH resolution without worsening fibrosis and at least one-stage fibrosis improvement. Older adults were part of the enrolled population, and subgroup reporting has described directionally consistent efficacy and adverse-event rates across age brackets. However, the trial was not powered to detect an age-by-treatment interaction, and specific percentages describing the geriatric subgroup's response rate or adverse-event frequency that circulate in secondary summaries should be verified against the primary trial publication before being treated as precise. The most common adverse events reported overall were gastrointestinal, primarily diarrhea and nausea, occurring more often than with placebo.

Decision framework: should this older adult start resmetirom?

This framework organizes the factors that should change a clinician's decision, rather than restate the label. It does not replace individualized dosing or diagnostic judgment.

Step 1 - Confirm the indication is right. Resmetirom is approved for MASH with F2-F3 fibrosis. If fibrosis stage is unconfirmed, or the patient has decompensated cirrhosis, this drug is off the approved pathway and specialist input is required before proceeding.

Step 2 - Screen for the three organ systems the drug stresses most.

Step 3 - Reconcile the medication list. Flag any statin (dose caps apply to rosuvastatin and pitavastatin), warfarin or other anticoagulant, levothyroxine, or CYP3A4/CYP2C8-dependent drug. Each of these needs a specific monitoring adjustment, not just a general caution (see interaction table below).

Step 4 - Weigh life expectancy and goals against monitoring burden. Resmetirom requires a monitoring schedule (thyroid, liver, kidney, sometimes INR and DEXA) that is meaningfully more intensive than a typical maintenance medication. For a patient with advanced frailty, life expectancy under roughly two years from competing illness, or inability to complete lab monitoring, watchful waiting with standard MASH risk-factor management (weight, glycemic control, cardiovascular risk reduction) may be more appropriate than starting a new hepatically active drug.

Step 5 - If starting, set the recheck triggers up front. Agree on when to hold the drug (ALT above 5x the upper limit of normal, or above 3x with symptoms such as jaundice or right-upper-quadrant pain) and when to stop permanently (ALT elevation with bilirubin above 2x the upper limit of normal, a possible Hy's Law pattern) before the first dose is taken, not after a lab result comes back abnormal.

Thyroid axis monitoring in older adults

Because resmetirom acts on the thyroid hormone receptor, even though it is designed to avoid the alpha-receptor effects linked to atrial fibrillation and bone loss, monitoring the axis matters more in a population where baseline rates of atrial fibrillation and osteoporosis are already elevated. A reasonable monitoring cadence, consistent with the FDA label's general recommendation to monitor liver function and standard endocrine practice for thyroid-axis-active drugs, is:

• Baseline: TSH, free T4
• 4 to 8 weeks after starting: repeat TSH, free T4
• Every 3 to 6 months through the first year: TSH with reflex free T4
• Annually thereafter if stable

For a patient already on levothyroxine, additive TSH suppression is a theoretical concern rather than a documented interaction in the label; recheck TSH after resmetirom initiation before adjusting the levothyroxine dose.

Drug interactions most relevant after 65

Kidney and hydration considerations

Resmetirom is not primarily cleared by the kidneys, and the label does not specify a renal dose adjustment. The pivotal trial excluded patients with eGFR below 30 mL/min/1.73 m², so there is no trial-derived safety data for that population, and use in advanced chronic kidney disease should be considered unstudied territory rather than simply "no adjustment needed." Diarrhea, the most frequently reported adverse event, can cause meaningful dehydration in an older adult with lower total body water, which in turn raises acute kidney injury risk, particularly on top of an ACE inhibitor, ARB, or SGLT2 inhibitor. Counsel patients to maintain fluid intake and set a low threshold for holding the drug during an acute GI illness.

Liver monitoring: the core paradox of a liver-targeted, liver-metabolized drug

Resmetirom treats liver disease while also being metabolized by the liver, which means baseline hepatic reserve affects both efficacy and drug handling. The FDA label recommends monitoring ALT, AST, and bilirubin, with a hold or discontinuation pathway triggered by defined thresholds (described in the decision framework above). For a geriatric patient with reduced hepatic reserve from cirrhotic changes, Child-Pugh B or C disease was excluded from the pivotal trial, and the drug should be used, if at all, only with specialist oversight in that setting.

When watchful waiting may be the safer choice

Not every older adult with MASH and fibrosis is a good candidate for a new hepatically active medication with an intensive monitoring schedule. Reasons to favor watchful waiting alongside standard risk-factor management (weight loss support, glycemic control, cardiovascular risk reduction) instead of starting resmetirom include advanced frailty, life expectancy shortened by competing illness, decompensated cirrhosis, or an inability to complete the recommended lab monitoring. This is a shared decision between patient and clinician, weighing fibrosis progression risk against treatment and monitoring burden, not an automatic exclusion based on age alone.

What remains unanswered

The pivotal trial ran 52 weeks. Longer-term geriatric safety, including cumulative effects of mild TSH suppression over years and outcomes in patients with more advanced age-related organ decline than the trial population represented, is not yet established. An outcomes trial intended to assess cardiovascular and liver-related endpoints over a longer horizon is reportedly underway; readers and clinicians should verify its current status and any geriatric subgroup reporting directly through ClinicalTrials.gov and the FDA label update history rather than relying on a fixed identifier, since trial registries and label supplements change over time. Post-marketing safety reporting through the FDA's adverse event reporting system will be the main source of real-world geriatric signal over the next several years, and specific percentages describing geriatric trial subgroup outcomes that appear in secondary sources should be checked against the primary trial publication before being used in patient counseling.

A note on sources. This draft intentionally omits several specific journal and PubMed citations that appeared in an earlier version of this page, because they could not be verified against the claims they were attached to. The FDA prescribing information is the verified anchor for dosing, monitoring thresholds, and the statin interaction caps described above. Trial efficacy and adverse-event percentages, thyroid-fracture risk estimates, and the earlier attributed quotations from a named physician and a professional society should be checked against the original trial publication and guideline text before this page is published, and any that cannot be verified should be removed or rewritten as general, unattributed statements.